The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and – last but not least – regulatory issues. The theme of the conference this year was “Taking the temperature of bioanalysis”, which is exactly what the guys have come back to discuss here for the 83rd episode of “The Weekly Bioanalysis” podcast!
To view/listen to the episode of “the Weekly Bioanalysis” click the play button below!
“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.
KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
You can always find the latest episode of “The Weekly Bioanalysis” here,
but you can also subscribe to the podcast on Apple Podcasts or any of the major podcast distribution channels!
We would love to hear from you about questions you have from our podcast – or even feedback on how we could improve it!
Please use the form below to reach out to us.